How would you integrate immunotherapy into the treatment of a patient with recurrent, widely metastatic gastric adenocarcinoma after initial treatment with perioperative EOX and subtotal gastrectomy?
CPS score of 40%. How and when do you incorporate immunotherapy into the treatment of metastatic gastric adenocarcinoma?
Community PollStarted
What would be your next treatment for a patient with MSS, HER2-, PD-L1+ symptomatic metastatic gastric cancer 2 years after perioperative EOX with grade 2 neuropathy?
42 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Memorial Sloan Kettering Cancer Center
Answered on
I agree with my friend, @Dr. First Last.
Firstly, I hope that this is an entirely theoretical scenario or that the patient received EOX many years ago, prior to the FLOT4 data that established FLOT as the current standard-of-care. As Dan also mentioned, for patients who cannot tolerate FLOT, FOLFOX ...
Join for free or sign in to see the full answer